GEN-MKT-18-7897-A
Oct 29, 2024 | Blogs, Echo® MS+ system, Pharma, QTRAP / Triple Quad, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
Drug development is a challenging process that requires diverse analytical solutions and the expertise of research scientists.
Within drug discovery confident go/no-go decisions need to be made as quickly as possible. Often, highly sensitive techniques are needed to accurately monitor concentrations of biomarkers, therapeutic candidates, and their metabolites. QA/QC laboratories need consistent performance everyday over many years.
We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
The guide covers bio/pharmaceutical quantitative assays from discovery to QA/QC, for large and small molecules. Discussing challenges regularly faced by scientists, along with potential solutions.
Download the guide >
The guide includes comprehensive chapters addressing multiple challenges and solutions regularly faced in drug development.
Discovery
Development (Small and large molecules)
Regulatory solutions
QA/QC and lot release
Products
Download the guide here >
Ultra‑low reporting limits, expanding target lists, and the constant risk of background contamination mean that even small missteps before injection can compromise data integrity. PFAS can be introduced at nearly every stage of prep, from sampling containers and PPE to SPE cartridges, filters, solvents, and lab consumables, making contamination control as critical as analyte recovery.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
Posted by
You must be logged in to post a comment.
Share this post with your network